<?xml version="1.0" encoding="UTF-8"?>
<p>A great chance for potential combination therapy with baracitinib is present due to its favorable pharmacokinetic properties such as low plasma protein binding affinity, minimal interaction with CYP enzymes, and drug transporters [
 <xref rid="B73-pharmaceuticals-13-00096" ref-type="bibr">73</xref>]. Currently, in the COVID-19 outbreak, baricitinib is being combined with different antivirals, such as lopinavir, ritonavir, and remdesivir, since this combination would decrease viral infectivity, viral replication, and the exaggerated host inflammatory response.
</p>
